Authentication technology developer raises series A funding led by Debiopharm Investment and Swisscom Ventures.
KeyLemon, a Switzerland-based startup which provides face and speaker authentication technology, has closed a reported $1.5m series A funding round co-led by Debiopharm Investment, the private equity and venture capital division of Debiopharm Group, a Switzerland-based group of biopharmaceutical companies, and Swisscom Ventures, the corporate venturing arm of Switzerland-based leading telecom operator Swisscom.
The funding will be used to support KeyLemon’s growth and to develop new technologies and customer solutions.
Previously, in March 2011, KeyLemon raised a…
